On September 16, the Yangming Biotech commercial high-end manufacturing platform project was signed and launched in Wuxi. The project includes the layout of novel biologics production lines and supporting process development laboratories. The product pipeline covers cutting-edge biologics categories such as monoclonal antibodies, bispecific antibodies, and Fc fusion proteins.

On September 16, the Yangming Biotech commercial high-end manufacturing platform project was signed and launched in Wuxi. The project includes the layout of novel biologics production lines and supporting process development laboratories. The product pipeline covers cutting-edge biologics categories such as monoclonal antibodies, bispecific antibodies, and Fc fusion proteins.